EpimAb Biotherapeutics, Innovent Biologics establish multi-target bispecific antibody collaboration
Under the terms of the agreement, Innovent will gain access to EpimAb’s proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform to develop multiple bispecific antibodies for the Chinese market, including the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.